{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:41:40Z","timestamp":1784616100959,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H02513"],"award-info":[{"award-number":["22H02513"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.tvjl.2024.106264","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T22:52:41Z","timestamp":1730760761000},"page":"106264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antitumor effects of inhibitors of ERK and Akt pathways in canine histiocytic sarcoma cell lines"],"prefix":"10.1016","volume":"308","author":[{"given":"H.","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tomiyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Goto-Koshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonkobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2024.106264_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/ml200004g","article-title":"Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)","volume":"2","author":"Abe","year":"2011","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.tvjl.2024.106264_bib2","first-page":"1","article-title":"Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma","author":"Asada","year":"2023","journal-title":"Scientific Reports"},{"key":"10.1016\/j.tvjl.2024.106264_bib3","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1292\/jvms.68.1343","article-title":"Establishment and biological characterization of canine histiocytic sarcoma cell lines","volume":"68","author":"Azakami","year":"2006","journal-title":"Journal of Veterinary Medical Science"},{"key":"10.1016\/j.tvjl.2024.106264_bib4","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/j.tvjl.2024.106264_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1746-6148-8-73","article-title":"The class I PI3K\/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention","volume":"8","author":"Chen","year":"2012","journal-title":"BMC veterinary Research"},{"key":"10.1016\/j.tvjl.2024.106264_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.tvjl.2024.106264_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mol.119.115808","article-title":"Identifying the ErbB\/MAPK signaling cascade as a therapeutic target in canine bladder cancer","volume":"96","author":"Cronise","year":"2019","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.tvjl.2024.106264_bib8","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/0008-5472.CAN-10-3647","article-title":"STAT3 mediates resistance to MEK inhibitor through microRNA miR-17","volume":"71","author":"Dai","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2024.106264_bib9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nature Reviews Drug discovery"},{"key":"10.1016\/j.tvjl.2024.106264_bib10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.tvjl.2024.106264_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.tvjl.2024.106264_bib12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbrc.2020.09.143","article-title":"Inhibition of Akt\/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer","volume":"533","author":"Haga","year":"2020","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.tvjl.2024.106264_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.32991","article-title":"PTPN11 mutations in canine and human disseminated histiocytic sarcoma","author":"H\u00e9dan","year":"2020","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.tvjl.2024.106264_bib14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.tvjl.2024.106264_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tvjl.2012.12.016","article-title":"Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells","volume":"196","author":"Ito","year":"2013","journal-title":"Veterinary Journal"},{"key":"10.1016\/j.tvjl.2024.106264_bib16","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/jvp.12449","article-title":"Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2","volume":"41","author":"Ito","year":"2018","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"10.1016\/j.tvjl.2024.106264_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGFReceptors: Cancer Biology and Therapeutics","volume":"34","author":"Katoh","year":"2013","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.tvjl.2024.106264_bib18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1541-7786.MCR-15-0506","article-title":"Phosphoproteomics reveals MAPK inhibitors enhance MET-and EGFR-driven AKT signaling in KRAS-mutant lung cancer","volume":"14","author":"Kim","year":"2016","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.tvjl.2024.106264_bib19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcp.12373","article-title":"Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours","volume":"78","author":"Leonowens","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.tvjl.2024.106264_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nature Genetics"},{"key":"10.1016\/j.tvjl.2024.106264_bib21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/leu.2008.3","article-title":"BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism","volume":"22","author":"Liu","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.tvjl.2024.106264_bib22","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.tvjl.2024.106264_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/vco.12437","article-title":"Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015)","volume":"16","author":"Marlowe","year":"2018","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2024.106264_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0300985813510413","article-title":"A Review of Histiocytic Diseases of Dogs and Cats","volume":"51","author":"Moore","year":"2014","journal-title":"Veterinary Pathology"},{"key":"10.1016\/j.tvjl.2024.106264_bib25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","article-title":"Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors","volume":"3","author":"Morris","year":"2013","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.tvjl.2024.106264_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cvsm.2019.04.009","article-title":"Histiocytic Sarcoma and Hemangiosarcoma Update","volume":"49","author":"Mullin","year":"2019","journal-title":"The Veterinary clinics of North America Small Animal Practice"},{"key":"10.1016\/j.tvjl.2024.106264_bib27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.12082","article-title":"Effects of food on the pharmacokinetics of ponatinib in healthy subjects","volume":"38","author":"Narasimhan","year":"2013","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.tvjl.2024.106264_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tvjl.2024.106264_bib29","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1939-1676.2010.0588.x","article-title":"Phase II, Open-Label Trial of Single-Agent CCNU in Dogs with Previously Untreated Histiocytic Sarcoma","volume":"24","author":"Rassnick","year":"2010","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2024.106264_bib30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1593\/neo.05355","article-title":"Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of Akt in vitro and in vivo","volume":"7","author":"Shi","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.tvjl.2024.106264_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski","year":"2007","journal-title":"Journal of veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2024.106264_bib32","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/0008-5472.CAN-05-4620","article-title":"Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival","volume":"66","author":"Song","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2024.106264_bib33","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/1535-7163.MCT-17-1273","article-title":"Targeting MEK in a translational model of histiocytic sarcoma","volume":"17","author":"Takada","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.tvjl.2024.106264_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/vco.12989","article-title":"Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial","author":"Takada","year":"2024","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2024.106264_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4132-0","article-title":"A novel canine histiocytic sarcoma cell line: Initial characterization and utilization for drug screening studies","volume":"18","author":"Takada","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tvjl.2024.106264_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.30802\/AALAS-CM-18-000065","article-title":"Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib","volume":"69","author":"Takada","year":"2019","journal-title":"Comparative Medicine"},{"key":"10.1016\/j.tvjl.2024.106264_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-5-23","article-title":"Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation","volume":"5","author":"Takahashi","year":"2012","journal-title":"Journal of Hematology and Oncology"},{"key":"10.1016\/j.tvjl.2024.106264_bib38","first-page":"161","article-title":"Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099","author":"Tani","year":"2019","journal-title":"Veterinary and Comparative Oncology"},{"key":"10.1016\/j.tvjl.2024.106264_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: The path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.tvjl.2024.106264_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02623551","article-title":"A macrophage-monocyte cell line from a dog with malignant histiocytosis","volume":"24","author":"Wellman","year":"1988","journal-title":"In Vitro Cellular Developmental Biology"},{"key":"10.1016\/j.tvjl.2024.106264_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-194","article-title":"Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma","volume":"13","author":"Wong","year":"2014","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.tvjl.2024.106264_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tranon.2016.12.008","article-title":"Dual Inhibition of PI3K\/AKT and MEK\/ERK pathways induces synergistic antitumor effects in diffuse intrinsic pontine glioma cells","volume":"10","author":"Wu","year":"2017","journal-title":"Translational Oncology"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109002332400203X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109002332400203X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:08:53Z","timestamp":1732928933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109002332400203X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"alternative-id":["S109002332400203X"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2024.106264","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor effects of inhibitors of ERK and Akt pathways in canine histiocytic sarcoma cell lines","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2024.106264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106264"}}